UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 良性乳房疾患の概要 overview of benign breast disease
2. 乳房の発達および形態 breast development and morphology
3. 乳房生検 breast biopsy
4. 乳房肉腫：疫学、危険因子、臨床症状、診断、およびステージング breast sarcoma epidemiology risk factors clinical presentation diagnosis and staging

English Journal

A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with ductal carcinoma in situ of the breast.

Kondo T1, Hayashi N1, Ohde S2, Suzuki K3, Yoshida A1, Yagata H1, Niikura N4, Iwamoto T5, Kida K1, Murai M1, Takahashi Y1, Tsunoda H6, Nakamura S7, Yamauchi H1.
Journal of surgical oncology.J Surg Oncol.2015 Sep 8. doi: 10.1002/jso.24037. [Epub ahead of print]
BACKGROUND: The aims of this study were to determine clinicopathological factors associated with postoperative upstaging to invasive carcinoma in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS) and to develop a model to predict the risk of upstaging.METHODS: Pre- and post-oper
PMID 26346047

Basal Cytokeratin Phenotypes of Myoepithelial Cells Indicates the Origin of Ductal Carcinomas In Situ of the Breast.

Chen L1, Yin X, Lu S, Chen G, Dong L.
Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry.Appl Immunohistochem Mol Morphol.2015 Sep;23(8):558-64. doi: 10.1097/PAI.0000000000000123.
Terminal duct lobular unit (TDLU) is widely accepted as the origin of ductal carcinoma in situ of breast. The differentiation states of myoepithelial cells of breast ductal system hint the development of breast hyperplastic lesions. Basal cytokeratin (CK) phenotypes indicate the differentiation of m
PMID 26336082

Gene signature model for breast cancer risk prediction for women with sclerosing adenosis.

Degnim AC1, Nassar A, Stallings-Mann M, Keith Anderson S, Oberg AL, Vierkant RA, Frank RD, Wang C, Winham SJ, Frost MH, Hartmann LC, Visscher DW, Radisky DC.
Breast cancer research and treatment.Breast Cancer Res Treat.2015 Aug;152(3):687-94. doi: 10.1007/s10549-015-3513-1. Epub 2015 Jul 23.
Benign breast disease (BBD) is diagnosed in 1-2 million women/year in the US, and while these patients are known to be at substantially increased risk for subsequent development of breast cancer, existing models for risk assessment perform poorly at the individual level. Here, we describe a DNA-mi
PMID 26202055